Gerresheimer has ended the discussions with private equity investors on a potential takeover offer.
The discussions have been ongoing since the beginning of 2025.
Dietmar Siemssen, CEO of Gerresheimer, said: “We have come to the conclusion that a continuation of the discussions is not in the best interest of our company and its stakeholders.
“Our focus remains firmly on our operating business and consistently implementing our corporate strategy to lead the company on a on a sustainable profitable growth path.”
Gerresheimer said it will continue to focus on the company’s strategic direction and the implementation of global growth projects.
The company will provide a strategy update at a Capital Market Day on October 15, 2025.
Among other things, the results of the strategic review of the moulded glass business will be presented.
In the mid-term, the company expects organic revenue growth of 6-9% and an organic adjusted EBITDA margin of 23-25%.
The group has a portfolio of systems and solutions for the pharmaceutical and biotech industry.
The acquisition of Bormioli Pharma has also further expanded the portfolio and opened new opportunities for system integration.
